Jaguar Health shares surge 13.29% after-hours after Napo Pharmaceuticals secures $18M licensing deal with Woodward Specialty.

Jaguar Health Inc. surged 13.29% in after-hours trading following its subsidiary Napo Pharmaceuticals’ $18 million licensing deal with Woodward Specialty, granting exclusive U.S. commercialization rights for Mytesi and Canalevia. The agreement includes an upfront payment of $16 million, with $2 million contingent on conditions and up to $17 million in potential milestone payments. Napo retains a buy-back option after five years if new FDA approvals are secured, enhancing long-term flexibility. The deal’s immediate cash infusion and future revenue potential align with the stock’s sharp post-market rally, overshadowing broader technical indicators of a bearish trend. The partnership also secures manufacturing and supply continuity for Mytesi, reinforcing operational stability. This strategic move addresses financial pressures and signals renewed investor confidence in Jaguar Health’s rare disease pipeline.